The peptide also promotes bone marrow stromal cell proliferation and osteogenic differentiation, providing more raw material for the bone-building process
Many patients with tingling or numbness begin to notice a reduction over months two and three, with further recovery beyond six months
Across all six studies, the safety findings were consistent: no serious adverse events, no immunogenic responses, no changes in IGF-1, no glucose or insulin disruption
May support accelerated healing of tendons, ligaments, muscles, and soft tissue injuries [1] [5]
Common claims include powerful cognitive enhancement, treatment for cognitive decline and dementia, neurogenesis and synaptic plasticity support, seven orders of magnitude more potent than BDNF, and memory improvement and brain repair
Semaglutide is a GLP-1 agonist, not a triple agonist, so the CagriSema programme tells you nothing about retatrutide as a partner for cagrilintide